Daily Signals
2696 companies scored · 2026-10-16 run in progress: 298 of ~5380 signals so far · Alpha · vs marketSwitch to Total · 30D 90D
Distribution of the day's forecasts
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
303 companies
Sorted by market cap ↓ · forecast rankings are part of the paid plans
| Ticker | Rating | 90D | Δ | |
|---|---|---|---|---|
| LABSTANDARD BIOTOOLS INC. | Unlock rating and forecasts | |||
| BIOABioAge Labs, Inc. | Unlock rating and forecasts | |||
| AMRNAMARIN CORP PLC\UK | +0.17% | · | ||
| LFCRLIFECORE BIOMEDICAL, INC. \DE\ | -0.68% | · | ||
| IMRXImmuneering Corp | Unlock rating and forecasts | |||
| FATEFATE THERAPEUTICS INC | Unlock rating and forecasts | |||
| SABSSAB Biotherapeutics, Inc. | +0.02% | · | ||
| GLSIGreenwich LifeSciences, Inc. | Unlock rating and forecasts | |||
| SIGASIGA TECHNOLOGIES INC | +0.16% | · | ||
| NATRNATURES SUNSHINE PRODUCTS INC | Unlock rating and forecasts | |||
| KROSKeros Therapeutics, Inc. | +0.10% | ▼ 2 | ||
| LXEOLexeo Therapeutics, Inc. | Unlock rating and forecasts | |||
| ALECAlector, Inc. | Unlock rating and forecasts | |||
| PLXProtalix BioTherapeutics, Inc. | Unlock rating and forecasts | |||
| NAGENiagen Bioscience, Inc. | -0.67% | · | ||
| AKBAAkebia Therapeutics, Inc. | Unlock rating and forecasts | |||
| RNACCartesian Therapeutics, Inc. | Unlock rating and forecasts | |||
| ADCTADC Therapeutics SA | Unlock rating and forecasts | |||
| CGENCOMPUGEN LTD | -0.22% | · | ||
| ACOGAlpha Cognition Inc. | Unlock rating and forecasts | |||
| UPBUpstream Bio, Inc. | Unlock rating and forecasts | |||
| SIONSionna Therapeutics, Inc. | Unlock rating and forecasts | |||
| IVVDInvivyd, Inc. | Unlock rating and forecasts | |||
| TRDAEntrada Therapeutics, Inc. | Unlock rating and forecasts | |||
| STROSUTRO BIOPHARMA, INC. | Unlock rating and forecasts | |||
| ORMPORAMED PHARMACEUTICALS INC. | Unlock rating and forecasts | |||
| ZNTLZentalis Pharmaceuticals, Inc. | Unlock rating and forecasts | |||
| CHRSCoherus Oncology, Inc. | Unlock rating and forecasts | |||
| CMPXCompass Therapeutics, Inc. | Unlock rating and forecasts | |||
| PEPGPepGen Inc. | Unlock rating and forecasts | |||
| MDWDMediWound Ltd. | -0.80% | ▲ 1 | ||
| NBPNovaBridge Biosciences | -0.64% | · | ||
| MOLNMOLECULAR PARTNERS AG | +0.14% | · | ||
| ORGOOrganogenesis Holdings Inc. | Unlock rating and forecasts | |||
| TARAProtara Therapeutics, Inc. | Unlock rating and forecasts | |||
| NKTXNkarta, Inc. | Unlock rating and forecasts | |||
| DERMJourney Medical Corp | Unlock rating and forecasts | |||
| ANTXAN2 Therapeutics, Inc. | Unlock rating and forecasts | |||
| KRROKorro Bio, Inc. | Unlock rating and forecasts | |||
| HUMAHumacyte, Inc. | Unlock rating and forecasts | |||
| ENGNenGene Therapeutics Inc. | +0.06% | ▼ 2 | ||
| OTLKOutlook Therapeutics, Inc. | Unlock rating and forecasts | |||
| ARMPArmata Pharmaceuticals, Inc. | Unlock rating and forecasts | |||
| CLLSCellectis S.A. | -0.04% | · | ||
| FHTXFoghorn Therapeutics Inc. | Unlock rating and forecasts | |||
| NERVMinerva Neurosciences, Inc. | Unlock rating and forecasts | |||
| MISTMilestone Pharmaceuticals Inc. | +0.22% | ▼ 1 | ||
| SPRBSPRUCE BIOSCIENCES, INC. | -0.67% | ▲ 1 | ||
| LENZLENZ Therapeutics, Inc. | Unlock rating and forecasts | |||
| INOINOVIO PHARMACEUTICALS, INC. | Unlock rating and forecasts | |||
By sector
Median 90D forecast per sector. Click to filter.
Rating changes
Unlock the full ranking
Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.
See plans Create a free accountRatings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.